Accessible text: pCPA Dashboard

Accessible text for the pCPA October 2025 Dashboard

Data effective: August 31, 2025

For questions regarding this report, please contact: [email protected]

Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA’s inception, 710 negotiations have reached a letter of intent (LOI), including:

  • 259 for oncology
  • 78 for biosimilars
  • 88 for expensive drugs for rare diseases (EDRD)
Data for stacked line graph: Letters of intent
MonthBiosimilarEDRDOther non-oncologyOther oncology
Jun 2015063924
Jul 2015064125
Aug 2015064326
Sep 2015064526
Oct 2015064727
Nov 2015064728
Dec 2015164730
Jan 2016165030
Feb 2016165130
Mar 2016165331
Apr 2016175631
May 2016176031
Jun 2016176132
Jul 2016176233
Aug 2016176334
Sep 2016186534
Oct 20161116536
Nov 20162126637
Dec 20162126737
Jan 20173126837
Feb 20173126841
Mar 20173127541
Apr 20173128041
May 20173128141
Jun 20173138144
Jul 20174138447
Aug 20175138548
Sep 20175148550
Oct 20175148551
Nov 20176158751
Dec 20176168956
Jan 20186179359
Feb 20186189460
Mar 20186189860
Apr 20186189961
May 201861910061
Jun 201862010062
Jul 201862110163
Aug 201872210566
Sep 201872411067
Oct 201872511367
Nov 201872511567
Dec 201872811870
Jan 201972812372
Feb 201972812375
Mar 201982812976
Apr 201982813081
May 201982813282
Jun 201982813482
Jul 201982913782
Aug 201993014083
Sep 2019103014287
Oct 2019113014589
Nov 2019133014791
Dec 2019143015594
Jan 2020143015694
Feb 2020143115695
Mar 2020153315797
Apr 2020153315998
May 20201635161104
Jun 20201635161104
Jul 20201936161105
Aug 20202036164108
Sep 20202036164109
Oct 20202136164110
Nov 20202138165112
Dec 20202239166114
Jan 20212239177115
Feb 20212739179116
Mar 20212740183118
Apr 20212840183119
May 20213040183121
Jun 20213140184122
Jul 20213142185122
Aug 20213142186124
Sep 20213342190129
Oct 20213444194129
Nov 20213645195133
Dec 20213645198134
Jan 20223645200138
Feb 20223746200141
Mar 20223847201147
Apr 20224148205148
May 20224148207149
Jun 20224648207152
Jul 20224649208153
Aug 20224650208155
Sep 20224651214158
Oct 20224653216159
Nov 20224656216162
Dec 20224857218165
Jan 20234857219168
Feb 20234958222168
Mar 20234959222168
Apr 20235160224181
May 20235162228181
Jun 20235264229190
Jul 20235265231192
Aug 20235366232194
Sep 20235466234195
Oct 20235466237196
Nov 20235669238199
Dec 20235669240201
Jan 20245670243202
Feb 20245773245202
Mar 20245873246205
Apr 20245873247206
May 20245874254206
Jun 20246074258207
Jul 20246374261208
Aug 20246374262214
Sep 20246374263220
Oct 20246375265222
Nov 20246376269225
Dec 20246678269228
Jan 20256679269229
Feb 20256680269234
Mar 20256980274239
Apr 20257380278242
May 20257480281247
Jun 20257582283249
Jul 20257784285256
Aug 20257888285259

Savings

Lower drug costs

pCPA activities saved jurisdictions an estimated $4.87B in 2023-24.

  • $3.94B from brand name drugs
  • $935M from generic drugs
  • Since 2010, cumulative savings are estimated to be $28.8B
Data for stacked bar chart: Savings
Fiscal YearBrand name drugsGeneric drug negotiationsTotal
FY 16/17$947,007,363$355,000,000$1,302,007,363
FY 17/18$1,263,644,399$740,000,000$2,003,644,399
FY 18/19$1,539,331,475$740,000,000$2,279,331,475
FY 19/20$1,847,496,049$740,000,000$2,587,496,049
FY 20/21$2,185,315,806$740,000,000$2,925,315,806
FY 21/22$2,667,069,216$750,000,000$3,417,069,216
FY 22/23$3,142,207,211$750,000,000$3,892,207,211
FY 23/24$3,715,798,849$913,979,661$4,629,778,510
FY 24/25$3,940,000,000$935,000,000$4,875,000,000

HTA and pCPA volumes

  • There has been very high activity in the first eight months of 2025, and the pCPA is projecting high volumes of health technology assessment (HTA) recommendations, and record volumes of negotiations engaged, and negotiations closed.
Data for bar charts: HTA and PCPA volumes

Three bar charts tracking number of CDA recommendations issued, pCPA files engaged, and pCPA files closed, with the first four months of 2025 and end of year projections for 2025 shown as a stacked bar.

YearCDA recommendations issuedpCPA files engagedpCPA files closed
2016645138
2017476068
2018627364
2019636882
2020576968
2021658574
2022828390
2023628193
2024799778
202548 (+34 projected for EOY) 86 (+43 projected for EOY) 91 (+46 projected for EOY) 

pCPA activity

  • The number of files in consideration was under 20 files for the first time in the post-COVID era.
  • The pCPA is committed to further decreasing the in-consideration timeline.
  • The number of active negotiations has significantly increased. In August, 2025, the pCPA negotiated a record 49. 
Data for line graphs: pCPA activity 

Two line graphs:

  • Files under consideration: HTA recommendation to pCPA engagement
  • Active negotiations: pCPA engagement to LOI
MonthFiles under consideration (average)Active Negotiations (average)
Jan 202128.433
Feb 20212732.75
Mar 202125.2534.75
Apr 202126.2533.25
May 202129.233
Jun 202128.2534.75
Jul 202128.543
Aug 202129.444.2
Sep 20213439.25
Oct 202135.235.8
Nov 20212841.25
Dec 20212345.75
Jan 20222543
Feb 202228.2542.75
Mar 202231.543.5
Apr 202232.2543.5
May 202231.841.8
Jun 20223035
Jul 202229.234.8
Aug 202230.536
Sep 20223432.5
Oct 202238.230.8
Nov 202236.2534.25
Dec 20223833.75
Jan 202335.435.4
Feb 202337.2537.5
Mar 202335.7541.75
Apr 202333.435.6
May 20233033
Jun 20232733.25
Jul 20232631.4
Aug 202325.526.25
Sep 20232428.25
Oct 202323.627.8
Nov 202324.2524
Dec 20232824
Jan 202427.7523.25
Feb 202428.521.75
Mar 202429.626.2
Apr 202431.7531.75
May 202434.529.25
Jun 202442.425.2
Jul 202441.7525
Aug 20243527.5
Sep 202424.437.8
Oct 20242041
Nov 202419.542
Dec 20242244.4
Jan 20252645.25
Feb 202526.2546
Mar 202519.845
Apr 202516.7543.75
May 202514.542
Jun 202514.838.8
Jul 202512.538.75
Aug 202515.246.8

pCPA timelines

  • All pCPA timeline metrics have improved between 2020 and 2025.
  • The typical months under consideration phase improved from 5.1 months to 2.1 months, a 59% decrease, and active negotiation timelines improved from 5.5 months to 3 months, a 46% decrease.
  • Between 2020 and 2025, the total timeline improved from 11 months to 6.5 months, a 41% decrease.
Data for bar chart: Time under consideration*
pCPA initiation yearMedian months
to pCPA milestones
20205.06
20213.81
20224.41
20234.04
20243.32
20252.10
Data for bar chart: Active negotiation time 
pCPA initiation yearMedian months to
pCPA milestones
20205.49
20214.31
20223.49
20233.88
20243.35
20252.99
Data for bar chart:  Total time*
pCPA initiation yearMedian months to
pCPA milestones
202010.93
20219.83
20229.67
20239.17
20246.79
20256.54

* Time under consideration and total timelines are only assessed for files arising from HTA recommendations, and excludes files that do not undergo negotiations. pCPA targets outlined in the brand process guidelines are approximately 2 months for file engagement, 4 months for active negotiations and 6 months combined.

Oncology drugs

  • The pCPA’s negotiation times for oncology drugs have decreased over time, shortened from 9 months for HTA reviews in 2020, to 6.4 months in 2025 (1.5 months to engagement and 3.9 months for active negotiation).
Data for bar chart: Oncology total timelines in 2024
pCPA initiation yearMedian months: HTA to pCPA completion
20209.14
20218.25
20228.98
20238.12
20245.68
20256.44
Data for bar chart: Negotiation stages in 2025
StageMedian months: pCPA milestones
Time under consideration1.55
Active negotiation time3.95
Total time6.44